Skip to main content
Year archive

OPKO Health Inc. — 2021 filings

All 167 regulatory filings released by OPKO Health Inc. (OPK) in 2021, sourced directly from the official regulator.

167 Filings
2021 Period
2021 filings (167)
Filing Released Lang
Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
Regulatory Filings
2021-12-23 English
Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
Report Publication Announcement
2021-12-23 English
OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test
Earnings Release Q4 2021
2021-12-08 English
OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test
Report Publication Announcement
2021-12-08 English
OPKO Health Announces the Passing of Director Dr. Richard Lerner
Board/Management Information
2021-12-06 English
OPKO Health Announces the Passing of Director Dr. Richard Lerner
Report Publication Announcement
2021-12-06 English
BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant merges in The U.S.
Regulatory Filings
2021-11-29 English
BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant merges in The U.S.
Report Publication Announcement
2021-11-29 English
OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
Report Publication Announcement
2021-11-29 English
OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
Report Publication Announcement
2021-11-29 English
FORM 10Q-THIRD QUARTER REPORT FOR 2021
Interim / Quarterly Report 9M 2021
2021-10-29 English
FORM 10Q-THIRD QUARTER REPORT FOR 2021
Report Publication Announcement
2021-10-29 English
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
Earnings Release Q3 2021
2021-10-29 English
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
Earnings Release Q3 2021
2021-10-29 English
OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021‎
Report Publication Announcement
2021-10-25 English
OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021‎
Report Publication Announcement
2021-10-25 English
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Earnings Release FY 2020
2021-09-25 English
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Report Publication Announcement
2021-09-25 English
GeneDx (subsidiary) Announces the Sequencing of More Than 300,000 Clinical Patient Exomes
Regulatory Filings
2021-09-21 English
GeneDx (subsidiary) Announces the Sequencing of More Than 300,000 Clinical Patient Exomes
Report Publication Announcement
2021-09-21 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Director's Dealing
2021-09-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Report Publication Announcement
2021-09-18 English
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
Regulatory Filings
2021-09-14 English
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
Report Publication Announcement
2021-09-14 English
8K: BioReference Laboratories, Inc, a subsidiary entered into an amended and restated credit agreement
Regulatory Filings
2021-09-04 English
8K: BioReference Laboratories, Inc, a subsidiary entered into an amended and restated credit agreement
Report Publication Announcement
2021-09-04 English
Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
Legal Proceedings Report
2021-08-31 English
Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
Report Publication Announcement
2021-08-31 English
will be participating in two upcoming investor conferences
Regulatory Filings
2021-08-30 English
will be participating in two upcoming investor conferences
Report Publication Announcement
2021-08-30 English
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program
Regulatory Filings
2021-08-28 English
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program
Report Publication Announcement
2021-08-28 English
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
M&A Activity
2021-08-16 English
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
Regulatory Filings
2021-08-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Director's Dealing
2021-08-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Regulatory Filings
2021-08-16 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4
Director's Dealing
2021-08-10 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4
Report Publication Announcement
2021-08-10 English
Form 8-K- 2021 Second Quarter Business Highlights and Financial Results
Earnings Release Q2 2021
2021-07-30 English
Form 8-K- 2021 Second Quarter Business Highlights and Financial Results
Report Publication Announcement
2021-07-30 English
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
Earnings Release Q2 2021
2021-07-30 English
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
Report Publication Announcement
2021-07-30 English
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
Earnings Release Q2 2021
2021-07-20 English
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
Report Publication Announcement
2021-07-20 English
Form 8-K-entered into an Exclusive License Agreement with CAMP4
Regulatory Filings
2021-07-12 English
Form 8-K-entered into an Exclusive License Agreement with CAMP4
Report Publication Announcement
2021-07-12 English
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
Regulatory Filings
2021-07-12 English
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
Report Publication Announcement
2021-07-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Yu, M.D., PhD. Alice Lin-Tsing
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Yu, M.D., PhD. Alice Lin-Tsing
Regulatory Filings
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Pfenniger, Jr. Richard C
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Pfenniger, Jr. Richard C
Regulatory Filings
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Paganelli John A
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Paganelli John A
Report Publication Announcement
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Medel Roger J. M.D
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Medel Roger J. M.D
Regulatory Filings
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Lerner Richard A
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Lerner Richard A
Report Publication Announcement
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Lachman Prem A. M.D
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Lachman Prem A. M.D
Regulatory Filings
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Krasno Richard M
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Krasno Richard M
Report Publication Announcement
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-06-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-06-26 English
8K- Termination of a Credit Agreement, result of annual meeting held on June 24, 2021
AGM Information
2021-06-26 English
8K- Termination of a Credit Agreement, result of annual meeting held on June 24, 2021
Report Publication Announcement
2021-06-26 English
Form 8-K-Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
Regulatory Filings
2021-06-24 English
Form 8-K-Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
Report Publication Announcement
2021-06-24 English
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry
Regulatory Filings
2021-06-22 English
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry
Report Publication Announcement
2021-06-22 English
Appoints Katherine Stueland as President and CEO of GeneDx
Board/Management Information
2021-06-22 English
Appoints Katherine Stueland as President and CEO of GeneDx
Report Publication Announcement
2021-06-22 English
to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
Regulatory Filings
2021-06-21 English
to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
Report Publication Announcement
2021-06-21 English
Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
M&A Activity
2021-06-17 Hebrew (modern)
Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
Report Publication Announcement
2021-06-17 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Director's Dealing
2021-06-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET Al
Report Publication Announcement
2021-06-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Cohen Jon R M.D.
Director's Dealing
2021-06-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Cohen Jon R M.D.
Regulatory Filings
2021-06-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET AL
Director's Dealing
2021-05-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FROST PHILLIP M.D. ET AL
Report Publication Announcement
2021-05-26 English
Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
Regulatory Filings
2021-05-24 English
Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
M&A Activity
2021-05-24 English
Termination of commercialization Agreement of Rayaldee in Japan
Regulatory Filings
2021-05-22 English
Termination of commercialization Agreement of Rayaldee in Japan
Report Publication Announcement
2021-05-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-05-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-05-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-05-08 English
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
Regulatory Filings
2021-05-08 English
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
Capital/Financing Update
2021-05-08 English
PR- OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
Capital/Financing Update
2021-05-08 English
PR- OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
Capital/Financing Update
2021-05-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-05-05 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-05-05 English
Notice regarding the availability of proxy materials for Annual Meeting of Stockholders to be held on June 24, 2021
Proxy Solicitation & Information Statement
2021-05-01 English
Notice regarding the availability of proxy materials for Annual Meeting of Stockholders to be held on June 24, 2021
Proxy Solicitation & Information Statement
2021-05-01 English
Notice of 2021 Annual Meeting of Stockholders to be held June 24, 2021,proxy statement
Proxy Solicitation & Information Statement
2021-05-01 English
Notice of 2021 Annual Meeting of Stockholders to be held June 24, 2021,proxy statement
AGM Information
2021-05-01 English
FORM 1O-Q: financial results for the quarter ended March 31, 2021.
Report Publication Announcement
2021-04-29 English
FORM 1O-Q: financial results for the quarter ended March 31, 2021.
Interim / Quarterly Report Q1 2021
2021-04-29 English
8K: operating and financial highlights for the quarter ended March 31, 2021.
Report Publication Announcement
2021-04-28 English
8K: operating and financial highlights for the quarter ended March 31, 2021.
Regulatory Filings Q1 2021
2021-04-28 English
Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year
Regulatory Filings
2021-04-27 English
Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year
Report Publication Announcement
2021-04-27 English
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021
Report Publication Announcement
2021-04-22 English
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021
Report Publication Announcement
2021-04-22 English
BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball
Regulatory Filings
2021-04-01 English
BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball
Report Publication Announcement
2021-04-01 English
BioReference Laboratories Expands COVID-19 School Testing Program
Regulatory Filings
2021-03-26 English
BioReference Laboratories Expands COVID-19 School Testing Program
Report Publication Announcement
2021-03-26 English
Amendment to Credit Agreement, dated as of March 12, 2021, by and among BioReference Laboratories, Inc., certain of its subsidiaries, and JPMorgan Chase Bank, N.A.
Regulatory Filings
2021-03-17 English
Amendment to Credit Agreement, dated as of March 12, 2021, by and among BioReference Laboratories, Inc., certain of its subsidiaries, and JPMorgan Chase Bank, N.A.
Regulatory Filings
2021-03-17 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-03-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-03-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-03-03 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-03-03 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-03-03 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Major Shareholding Notification
2021-03-03 English
The Board of Directors of OPKO Health appointed Prem A. Lachman, M.D. as a new director.
Board/Management Information
2021-03-03 English
The Board of Directors of OPKO Health appointed Prem A. Lachman, M.D. as a new director.
Board/Management Information
2021-03-03 English
EMA Accepts Marketing Application for Somatrogon
Regulatory Filings
2021-02-26 English
EMA Accepts Marketing Application for Somatrogon
Report Publication Announcement
2021-02-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2021-02-22 English
The Compensation Committee held a meeting to review compensation matters for the Company’s executive officers and non-executive employees
Remuneration Information
2021-02-22 English
The Compensation Committee held a meeting to review compensation matters for the Company’s executive officers and non-executive employees
Remuneration Information
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Regulatory Filings
2021-02-22 English
New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy
Regulatory Filings
2021-02-22 English
New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy
Report Publication Announcement
2021-02-22 English
FORM 10K-Annual Report on Form 10-K for the year ended December 31, 2020
Annual Report FY 2020
2021-02-20 English
FORM 10K-Annual Report on Form 10-K for the year ended December 31, 2020
Report Publication Announcement FY 2020
2021-02-20 English
FORM 8K-Reports 2020 Fourth Quarter Business Highlights and Financial Results
Earnings Release Q4 2020
2021-02-20 English
FORM 8K-Reports 2020 Fourth Quarter Business Highlights and Financial Results
Report Publication Announcement
2021-02-20 English
Immediate Report about change of identifying details
Regulatory Filings
2021-02-08 English
Technical correction-Rulfo F. Hernandez, resigned from his position as Chief Accounting Officer
Board/Management Information
2021-02-06 English
Technical correction-Rulfo F. Hernandez, resigned from his position as Chief Accounting Officer
Regulatory Filings
2021-02-06 English
OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021
Earnings Release Q4 2020
2021-02-03 English
OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021
Report Publication Announcement
2021-02-03 English
Rulfo F. Hernandez, resigned from his position as Chief Accounting Officer
Regulatory Filings
2021-02-01 English
Rulfo F. Hernandez, resigned from his position as Chief Accounting Officer
Report Publication Announcement
2021-02-01 English
New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency
Regulatory Filings
2021-01-28 English
New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency
Report Publication Announcement
2021-01-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Fishel Robert S. MD
Director's Dealing
2021-01-26 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Fishel Robert S. MD
Legal Proceedings Report
2021-01-26 English
OPKO Health’s GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia
Regulatory Filings
2021-01-26 English
OPKO Health’s GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia
Report Publication Announcement
2021-01-26 English
OPKO Health’s BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing
Regulatory Filings
2021-01-26 English
OPKO Health’s BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing
Report Publication Announcement
2021-01-26 English
8K-Company’s presentation as used in the 39th Annual J.P. Morgan Healthcare Conference
Investor Presentation
2021-01-13 English
8K-Company’s presentation as used in the 39th Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2021-01-13 English
OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, In-Home Diagnostic Service to Expand Digital Health Access
Regulatory Filings
2021-01-13 English
OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, In-Home Diagnostic Service to Expand Digital Health Access
Report Publication Announcement
2021-01-13 English
Present at the 39th Annual J.P. Morgan Healthcare Conference
Regulatory Filings
2021-01-05 English
Present at the 39th Annual J.P. Morgan Healthcare Conference
Regulatory Filings
2021-01-05 English
BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
Earnings Release Q4 2020
2021-01-04 English
BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
Report Publication Announcement
2021-01-04 English